A Study to Evaluate the Efficacy and Safety of IN-207907 Injection in Elderly Patients With Sarcopenia
Key claim: A clinical trial is testing whether IN-207907 injection at 120, 240, or 360 mg improves SPPB scores versus placebo in elderly patients with sarcopenia.
Abstract
The goal of this clinical trial is to learn if intervention can treat sarcopenia in the elderly. Researchers will compare IN-207907 120 mg, 240 mg, 360 mg and placebo to see if SPPB score improves.
Why this matters
Sarcopenia has few approved pharmacological therapies, so any dose-ranging RCT of a novel injectable that uses SPPB — a clinically meaningful physical performance endpoint rather than a surrogate biomarker — is a pipeline signal worth tracking. The trial’s design (placebo-controlled, three doses) will establish an initial efficacy and safety envelope, though no outcome data exist yet and the mechanism of IN-207907 is not disclosed in this record.